Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Sanford C. Bernstein Analyst Says

Natera (NASDAQ:NTRA) had its price target hoisted by investment analysts at Sanford C. Bernstein from $160.00 to $200.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Sanford C. Bernstein’s price target would suggest a potential upside of 14.29% from the company’s previous close.

NTRA has been the topic of several other research reports. Craig Hallum increased their price target on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. increased their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Canaccord Genuity Group increased their price target on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Piper Sandler increased their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Finally, Morgan Stanley increased their price target on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $158.00.

Natera Stock Down 0.9 %

Natera stock opened at $175.00 on Friday. Natera has a twelve month low of $59.80 and a twelve month high of $177.00. The company’s 50-day moving average price is $160.14 and its two-hundred day moving average price is $132.29. The stock has a market cap of $23.10 billion, a P/E ratio of -99.43 and a beta of 1.65. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the firm earned ($0.95) earnings per share. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, analysts expect that Natera will post -1.61 EPS for the current year.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 669 shares of Natera stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the sale, the insider now directly owns 114,142 shares of the company’s stock, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,523 shares of Natera stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now directly owns 191,163 shares of the company’s stock, valued at approximately $24,927,655.20. This trade represents a 2.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,932 shares of company stock worth $20,635,430. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new stake in Natera in the second quarter valued at $28,000. Quarry LP increased its stake in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. Covestor Ltd grew its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.